Version Française

Contribute to the regulation by quality and efficiency

Search

impression
TRANSPARENCY COMMITTEE OPINION

ZYDELIG (idelalisib), kinase inhibitor

Active substance (DCI)
  • idélalisib
ONCOLOGY - NEW MEDICINAL PRODUCT

Reason for request
Inclusion

Date 17 June 2015

Moderate improvement, in combination with rituximab, in chronic lymphocytic leukaemia in second-line and subsequent therapy, and in the first line in case of deletion 17p or TP53 mutation.

Minor improvement in follicular lymphoma refractory to two prior lines of treatment.

  • ZYDELIG has Marketing Authorisation in two indications:

    - in combination with rituximab in the treatment of adults with chronic lymphocytic leukaemia (CLL) who have received at least one prior treatment or in the first line in case of deletion 17p or TP53 mutation, in patients for whom immunochemotherapy is not appropriate.

     - in monotherapy in the treatment of adults with follicular lymphoma (FL) refractory to two prior lines of treatment. 

  • In treatment of CLL, in 2nd-line and subsequent therapy, ZYDELIG in combination with MABTHERA (rituximab) has shown an improvement in progression-free survival, in overall survival and in quality of life compared with rituximab alone.
  • In 1st line treatment of patients with a deletion 17p (del17p) or TP53 mutation, efficacy data are very limited.
  • In refractory FL, therapeutic benefit was observed in a non-comparative study based on the overall response rate. ZYDELIG as monotherapy is an alternative treatment in patients with FL refractory to two prior lines of treatment.

 

 


Actual benefit

Important

-


Improvement in actual benefit

III (modéré)

-

IV (mineur)


Therapeutic use

-

-

Documents

Economic analysis

English version

ATC Code
  • L01XX47
Laboratory / Manufacturer
idelalisib

Presentation

-

Posted on Feb 29 2016